Tris' allergy drug for children gets FDA OK

04/4/2013 | Drug Store News

The FDA approved Tris Pharma's Karbinal ER, or carbinoxamine maleate, for pediatric patients 2 years and older, to treat seasonal and perennial allergic rhinitis. The treatment is the first extended-release histamine receptor blocking agent for children's allergies, Tris said.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA